Abstract
The PI3K/Akt/mTOR signaling pathway plays a key role in diverse physiologic processes. It is also central to many aspects of the malignant process. Genetic phenomena that lead to constitutive pathway activation are common in human cancer; the most relevant are mutations affecting the catalytic subunit of PI3K and loss of function of the PTEN tumor suppressor. These factors have made this important cascade attractive as a potential target for cancer therapeutics. A host of inhibitors are now in various stages of development that target key nodes within the PI3K pathway. To date, however, the efficacy of these agents has fallen short of expectation, with at least one possible explanation being the presence of feedback loops and cross-talk that exists within and between PI3K and other signaling pathways. Accordingly, enthusiasm is again high as strategies employing therapeutic combinations are gaining pace, with encouraging results documented in both preclinical studies and emerging clinical trials. Here, we review the agents that have reached evaluation in early phase clinical studies of human subjects with cancer, and discuss the rationale for and use of novel drug combinations.
Keywords: PI3K, PIK3CA, PTEN, mTOR, Akt, PI3K inhibitor, therapeutic combination, clinical trial, signaling pathway, tumor suppressor
Current Pharmaceutical Design
Title:PI3K Pathway Inhibitors: Better Not Left Alone
Volume: 19 Issue: 5
Author(s): Ben Markman, Jessica J. Tao and Maurizio Scaltriti
Affiliation:
Keywords: PI3K, PIK3CA, PTEN, mTOR, Akt, PI3K inhibitor, therapeutic combination, clinical trial, signaling pathway, tumor suppressor
Abstract: The PI3K/Akt/mTOR signaling pathway plays a key role in diverse physiologic processes. It is also central to many aspects of the malignant process. Genetic phenomena that lead to constitutive pathway activation are common in human cancer; the most relevant are mutations affecting the catalytic subunit of PI3K and loss of function of the PTEN tumor suppressor. These factors have made this important cascade attractive as a potential target for cancer therapeutics. A host of inhibitors are now in various stages of development that target key nodes within the PI3K pathway. To date, however, the efficacy of these agents has fallen short of expectation, with at least one possible explanation being the presence of feedback loops and cross-talk that exists within and between PI3K and other signaling pathways. Accordingly, enthusiasm is again high as strategies employing therapeutic combinations are gaining pace, with encouraging results documented in both preclinical studies and emerging clinical trials. Here, we review the agents that have reached evaluation in early phase clinical studies of human subjects with cancer, and discuss the rationale for and use of novel drug combinations.
Export Options
About this article
Cite this article as:
Markman Ben, J. Tao Jessica and Scaltriti Maurizio, PI3K Pathway Inhibitors: Better Not Left Alone, Current Pharmaceutical Design 2013; 19 (5) . https://dx.doi.org/10.2174/1381612811306050895
DOI https://dx.doi.org/10.2174/1381612811306050895 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inflammation and Chronic Heart Failure: From Biomarkers to Novel Anti-inflammatory Therapeutic Strategies
Medicinal Chemistry Long Non-Coding RNA GAS5 in Age-Related Diseases
Current Medicinal Chemistry Recent Progress and Related Patents on the Applications of Bone Marrow-Derived Stem/Progenitor Cells in Regenerative Medicine and Cancer Therapies
Recent Patents on Regenerative Medicine Induction and Escalation Therapies in Multiple Sclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Ignored Avenues in Alpha-Synuclein Associated Proteopathy
CNS & Neurological Disorders - Drug Targets Modulation of Collagen Turnover in Cardiovascular Disease
Current Pharmaceutical Design Antiarrhythmic Potential of Drugs Targeting the Cardiac Ryanodine Receptor Ca<sup>2+</sup> Release Channel: Case Study of Dantrolene
Current Pharmaceutical Design Endothelin-1 Signaling in Vascular Physiology and Pathophysiology
Current Vascular Pharmacology Proteomic and Bioinformatic Analysis of Trypanosoma cruzi Chemotherapy and Potential Drug Targets: New Pieces for an Old Puzzle
Current Drug Targets Prolylcarboxypeptidase Gene Expression in the Heart and Kidney: Effects of Obesity and Diabetes
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role of Transcription Factors in the Formation of an Arrhythmogenic Substrate in Congestive Human Heart Failure
Current Medicinal Chemistry Risk Factors for Heart Failure Progression and Outcomes
Current Cardiology Reviews Bariatric Surgery: Indications, Safety and Efficacy
Current Pharmaceutical Design The Ubiquitin-Proteasome Pathway and Resistance Mechanisms Developed Against the Proteasomal Inhibitors in Cancer Cells
Current Drug Targets Mitochondrial Injury and Targeted Intervention in Septic Cardiomyopathy
Current Pharmaceutical Design Nanocarriers in the Delivery of Hydroxychloroquine to the Respiratory System: An Alternative to COVID-19
Current Drug Delivery Molecular Imaging of Myocardial Inflammation: More Evidence Toward a Causative Role in Cardiovascular Disease
Current Radiopharmaceuticals Recent Developments in Nanoparticle Based Targeted Delivery of Chemotherapeutics
Current Bioactive Compounds Cardiac Protection via Metabolic Modulation: An Emerging Role for Incretin-Based Therapies?
Cardiovascular & Hematological Agents in Medicinal Chemistry AMPK As A Target in Rare Diseases
Current Drug Targets